Dianosic, a Strasbourg, France-based deeptech company specializing in the development of innovative solutions for the treatment of ENT conditions, raised €4.7M in funding.
Backers included Wiseed, Fondation Force, and Bpifrance’s deeptech.
The company intends to use the funds to finance its preclinical in vivo study and launch the phase I clinical trial of its ARIS-R solution for the treatment of chronic allergic rhinitis. In parallel, the company will also continue to develop treatment options for chronic sinusitis (with its ARIS-S solution) and explore other potential applications in the field of ENT. Additionally, the new funding will be used to enhance the technical capability of the team.
RELATED: Treace Medical Concepts, Inc. receives a $417,000 investment from Quantbot Technologies LP
Co-founded by president Marc Augustin and CEO Philippe Bastide, Dianosic specializes in the development of innovative treatment solutions for debilitating ENT conditions. The company is also behind the CE-marked and FDA-registered CAVI-T medical device, an asymmetrical intranasal balloon designed to stop spontaneous or post-operative bleeding with low pressure compression. This device has been commercially available in Europe and the Middle East since 2021.
Prof. Christian Debry, the third co-founder and head of the ENT – Head & Neck Surgery Department at Strasbourg University Hospital, acts as a scientific advisor to the company.
Dianosic was co-incubated by SEMIA and Quest for health.
